ELOXHealthcare · BiotechnologyELOX Stock Forecast: Eloxx Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering Eloxx Pharmaceuticals, Inc. hold a median 12-month price target of $42 — +138.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
ELOX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Eloxx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (100): Smaller than most of the companies we track.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Eloxx Pharmaceuticals, Inc. — and when they’d sell — is the membership.
ELOX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ELOX, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +138.1% from it.
Of the 20 most recent actions, 1 moved their price target up and 8 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 July 2026 | LifeSci Capital | Initiates | Outperform | $40 |
| 20 July 2026 | Guggenheim | Initiates | Buy | $43 |
| 11 July 2023 | Oppenheimer | Maintains | Outperform | $50 → $55 |
| 11 July 2023 | Oppenheimer | Maintains | Outperform | — |
| 6 Apr 2023 | Oppenheimer | Reiterates | Outperform | — |
| 23 May 2022 | Piper Sandler | Maintains | Overweight | $4.00 → $1.50 |
| 9 May 2022 | HC Wainwright & Co. | Maintains | Neutral | $1.00 → $0.50 |
| 17 Dec 2021 | Oppenheimer | Initiates | Outperform | — |
| 18 Nov 2021 | HC Wainwright & Co. | Maintains | Neutral | $2.00 → $1.00 |
| 11 Nov 2021 | HC Wainwright & Co. | Maintains | Neutral | $3.00 → $2.00 |
| 30 June 2021 | Mizuho | Initiates | Buy | — |
| 27 May 2021 | B. Riley Securities | Initiates | Buy | — |
| 11 June 2020 | Citigroup | Downgrade | Neutral | $11 → $4.00 |
| 8 May 2020 | Janney Capital | Maintains | Buy | — |
| 8 May 2020 | Janney Montgomery Scott | Maintains | Buy | $13 → $10 |
| 6 Mar 2020 | H.C. Wainwright | Reiterates | Neutral | — |
| 6 Mar 2020 | HC Wainwright & Co. | Reiterates | Neutral | $10 → $3.00 |
| 6 Sept 2019 | Janney Capital | Initiates | Buy | — |
| 15 May 2019 | Canaccord Genuity | Maintains | Buy | $20 → $17 |
| 24 Dec 2018 | H.C. Wainwright | Initiates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ELOX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Eloxx Pharmaceuticals, Inc. (ELOX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −3.3×
- Price / sales
- —
- Price / book
- −10.3×
- EV / EBITDA
- −2.8×
Cheaper than 87% of US stocks
Cheaper than 97% of US stocks
Cheaper than 75% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 50.3%
- Return on assets
- −113.8%
- Dividend yield
- —
Higher than 93% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ELOX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELOX appears on the weeks it earns a place.
Frequently asked questions about ELOX stock
What is the ELOX stock price forecast for 2026-2027?
The 2 Wall Street analysts covering Eloxx Pharmaceuticals, Inc. have a median 12-month price target of $42, with estimates ranging from $40 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ELOX stock a buy right now?
Of the 2 analysts covering Eloxx Pharmaceuticals, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eloxx Pharmaceuticals, Inc. 16 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ELOX?
As at 1 Aug 2026, Eloxx Pharmaceuticals, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).
Will ELOX stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +138.1% from the last close, and Ticker Nerd's factor model ranks Eloxx Pharmaceuticals, Inc. 16 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ELOX stock forecast for 2030?
No analyst covering Eloxx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELOX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $43 over the next 12 months.
What does Eloxx Pharmaceuticals, Inc. do?
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare disease and other serious conditions.
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare disease and other serious conditions. The company’s current work centers on small-molecule genetic therapies, with lead programs aimed at addressing Alport syndrome, a rare kidney disorder, and additional research directed toward cancer and inflammatory diseases. Eloxx Pharmaceuticals applies proprietary technology platforms to discover and advance product candidates designed to modulate disease pathways and support human therapeutic applications. The company operates within the biotechnology sector, where its role is to translate scientific research into potential treatment options for unmet medical needs. Eloxx Pharmaceuticals, Inc. is headquartered in the United States and remains focused on advancing its current pipeline and platform-based drug development efforts.
CEO Mr. Sumit Aggarwal M.B.A. · 10 employees · United States · https://www.eloxxpharma.com